Table 5.
causality assessment summary of the suspected nOPV2 AESIΩ/AEFI¥ by State, March 13 - July 7, 2021, Nigeria
| Classification | Bayelsa n (%) | Delta n (%) | FCT n (%) | Kebbi n (%) | Niger n (%) | Sokoto n (%) | Zamfara n (%) | National n |
|---|---|---|---|---|---|---|---|---|
| Ineligible | 6 (9.4) | 4 (7.6) | 0 | 18 (34.0) | 6 (11.3) | 14 (26.4) | 6 (11.3) | 54 |
| Consistent causal association to nOPV2 immunization | 0 | 0 | 0 | 4 (100) | 0 | 0 | 0 | 4 |
| Inconsistent causal association to nOPV2 immunization | 17 (11.3) | 10 (6.3) | 2 (1.3) | 105 (63.8) | 12 (7.5) | 7 (4.4) | 9 (5.6) | 162 |
| Indeterminate | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 1 |
| Total | 23 (10.7) | 14 (6.7) | 2 (0.9) | 127 (56.9) | 18 (8) | 22 (10.2) | 15 (6.7) | 221 |
ΩNovel oral polio vaccine type 2 adverse event of special interest ¥Adverse event following immunization FCT: federal capital territory